Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in children

References

• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005 May 1; 103(9):1916–1924.
   Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011 Feb 15 52(4):e56–93.
   Google Scholar
• Smith TJ, Bohlke K, Armitage JO. Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015 Nov;11(6):511–513.
   Google Scholar
• Sassen SDT, Zwaan CM, der Sluis IM, et al., Pharmacokinetics and population pharmacokinetics in pediatric oncology. Pediatr Blood Cancer [Internet]. 2020 Apr;67(4). https://onlinelibrary.wiley.com/doi/10.1002/pbc.28132
   Google Scholar
• Moore DC. Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia. P T Peer-Rev J Formul Manage. 2016 Dec;41(12):765–768.
   Google Scholar
• Hakim H, Flynn PM, Knapp KM, et al. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2009 Sept;31(9):623–629.
   Google Scholar
• Lekshminarayanan A, Bhatt P, Linga VG, et al. National trends in hospitalization for fever and neutropenia in children with cancer, 2007-2014. J Pediatr. 2018 Nov;202:231–237.e3.
   Google Scholar
• Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007 Nov 15;45(10):1296–1304.
   Google Scholar
• Weiner H, Lunsford V, Potter P. Non-pharmacological strategies to prevent neutropenic fever in hematologic malignancy. Biol Blood Marrow Transplant. 2012 Feb;18(2):S391.
   Google Scholar
• Taggart C, Neumann N, Alonso PB, et al. Comparing a neutropenic diet to a food safety-based diet in pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019 July;25(7):1382–1386.
   Google Scholar
• Moody KM, Baker RA, Santizo RO, et al. A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients. Pediatr Blood Cancer. 2018 Jan;65(1):e26711.
   Google Scholar
• Ball S, Brown TJ, Das A, et al. Effect of neutropenic diet on infection rates in cancer patients with neutropenia: a meta-analysis of randomized controlled trials. Am J Clin Oncol. 2019 Mar;42(3):270–274.
   Google Scholar
• Aktekin E, Bay A, Yılmaz M. Granulocyte transfusion therapy in childhood. Indian J Hematol Blood Transfus. 2017 Sept;33(3):417–420.
   Google Scholar
• IBM Micromedex RED BOOK [Internet]. IBM Corporation; 2020 [cited 2021 Nov 29]. Available from: https://www.micromedexsolutions.com/micromedex2/librarian/CS/DA9AEC/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/D4B386/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/redbook.FindRedBook?navitem=topRedBook&isToolPage=true
   Google Scholar
• Prescribing information NEUPOGEN (filgrastim) [Internet]. FDA; 2021 [cited 2021 Nov 30]. Available from: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neupogen/neupogen_pi_hcp_english.pdf
   Google Scholar
• Prescribing information ZARXIO (filgrastim-sndz) [Internet]. FDA; 2015 [cited 2021 Nov 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125553lbl.pdf
   Google Scholar
• Prescribing information NIVESTYM (filgrastim-aafi) [Internet]. FDA; 2018 [cited 2021 Nov 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761080s000lbl.pdf
   Google Scholar
• Prescribing information GRANIX (tbo-filgrastim) [Internet]. FDA; 2014 [cited 2021 Nov 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125294s035lbl.pdf
   Google Scholar
• Prescribing information NEULASTA (pegfilgrastim) [Internet]. FDA; 2015 [cited 2021 Nov 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125031s180lbl.pdf
   Google Scholar
• Prescribing information FULPHILA (pegfilgrastim-jmdb) [Internet]. FDA; 2018 [cited 2021 Nov 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761075s000lbl.pdf
   Google Scholar
• Prescribing information UDENYCA (pegfilgrastim-cbqv) [Internet]. FDA; 2018 [cited 2021 Nov 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761039s000lbl.pdf
   Google Scholar
• Prescribing information ZIEXTENZO (pegfilgrastim-bmez) [Internet]. FDA; 2019 [cited 2021 Nov 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761045lbl.pdf
   Google Scholar
• Prescribing information NYVEPRIA (pegfilgrastim-apgf) [Internet]. FDA; 2020 [cited 2021 Nov 30].
   Google Scholar
• Prescribing information LEUKINE (sargramostim) [Internet]. FDA; 2018 [cited 2021 Nov 30. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103362s5240lbl.pdf
   Google Scholar
• Yang -B-B, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011 May;50(5):295–306.
   Google Scholar
• Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis. Cytokine. 2008 June;42(3):277–288.
   Google Scholar
• Stull DM, Bilmes R, Kim H, et al. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm. 2005 Jan 1;62(1):83–87. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761111lbl.pdf
   Google Scholar
• Spunt SL, Irving H, Frost J, et al. Open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol. 2010 Mar 10;28(8):1329–1336.
   Google Scholar
• Hematopoietic growth factors [Internet]. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology; 2021 [cited 2021 Nov 24]. Available from: http://www.nccn.org
   Google Scholar
• Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr. 1998 Nov 30;157(12):955–966.
   Google Scholar
• Li E, Mezzio DJ, Campbell D, et al. Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: a cost-effectiveness analysis. JCO Oncol Pract. 2021 Aug;17(8):e1235–45.
   Google Scholar
• Schlenker L, Manworren RCB. Timing of pegfilgrastim: association with febrile neutropenia in a pediatric solid and CNS tumor population. J Pediatr Oncol Nurs. 2021 Nov;38(6):375–384.
   Google Scholar
• Yankelevich M, Hoogstra DJ, Abrams J, et al. Delayed Granulocyte Colony-Stimulating Factor (G-CSF) administration after chemotherapy reduces total G-CSF doses without affecting neutrophil recovery in a randomized clinical study in children with solid tumors. Pediatr Hematol Oncol. 2020 November 16;37(8):665–675.
   Google Scholar
• Inaba H, Cao X, Pounds S, et al. Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. Cancer. 2011 Mar 15;117(6):1313–1320.
   Google Scholar
• Fox E, Widemann BC, Hawkins DS, et al. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res. 2009 Dec 1;15(23):7361–7367.
   Google Scholar
• Ladenstein R, Valteau-Couanet D, Brock P, et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol. 2010 July 20;28(21):3516–3524.
   Google Scholar
• Lehrnbecher T, Zimmermann M, Reinhardt D, et al. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007 Feb 1; 109(3):936–943.
   Google Scholar
• Little MA, Morland B, Chisholm J, et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol. 2002 Feb;38(2):98–103.
   Google Scholar
• Borinstein SC, Pollard J, Winter L, et al. Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors: pegfilgrastim use in children with solid tumors. Pediatr Blood Cancer. 2009 Sept;53(3):375–378.
   Google Scholar
• André N, Kababri ME, Bertrand P, et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs. 2007 Mar;18(3):277–281.
   Google Scholar
• Lyman GH, Lalla A, Barron RL, et al. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther. 2009 May;31(5):1092–1104.
   Google Scholar
• Lathia N, Isogai PK, Walker S, et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients receiving R-CHOP chemotherapy. Blood. 2009 Nov 20;114(22):2475.
   Google Scholar
• Ratti M, Tomasello G. Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. Expert Rev Clin Pharmacol. 2015 Jan 2;8(1):15–24.
   Google Scholar
• Link H, Illerhaus G, Martens UM, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer. 2021 May;29(5):2519–2527.
   Google Scholar
• Donadieu J, Beaupain B, Bou Mitri F, et al. Lenograstim and Filgrastim have a similar efficacy and safety profile in the treatment of chronic neutropenia. A study for the French SCN registry. Blood. 2020 Nov 5;136(Supplement 1):17–18.
   Google Scholar
• Hersh AL, Gerber JS, Hicks LA, et al. Lessons learned in antibiotic stewardship: fluoroquinolone use in pediatrics. J Pediatr Infect Dis Soc. 2015 Mar 1;4(1):57–59.
   Google Scholar
• Saleh EA, Schroeder DR, Hanson AC, et al. Guideline-concordant antibiotic prescribing for pediatric outpatients with otitis media, community-acquired pneumonia, and skin and soft tissue infections in a large multispecialty healthcare system. Clin Res Infect Dis. 2015 Jan 10;2(1):1010.
   Google Scholar